Evidence map›Paper›PMID 26772810›Full record

ArticleBMC biotechnology2016

Efficient generation of Rosa26 knock-in mice using CRISPR/Cas9 in C57BL/6 zygotes.

Van Trung Chu, Timm Weber, Robin Graf, Thomas Sommermann, Kerstin Petsch, Ulrike Sack, Pavel Volchkov, Klaus Rajewsky, Ralf Kühn

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 199 papers.

0numbers the graph read from it
0cells of the map it votes in
199citing papers in PubMed
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

199 citing papers in PubMed, 347 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

139 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Van Trung ChuMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany. VanTrung.Chu@mdc-berlin.de.
Timm WeberMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany. Timm.Weber@mdc-berlin.de.
Robin GrafMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany. Robin.graf@mdc-berlin.de.
Thomas SommermannMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany. Thomas.sommermann@mdc-berlin.de.
Kerstin PetschMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany. Kerstin.Petsch@mdc-berlin.de.
Ulrike SackPresent Address: Bayer Pharma AG Building S107, 13353, Berlin, Germany. ulrike.sack@bayer.com.
Pavel VolchkovHarvard University, Cambridge, MA, 02138, USA. vpwwww@gmail.com.
Klaus RajewskyMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany. Klaus.Rajewsky@mdc-berlin.de.
Ralf KühnMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany. ralf.kuehn@mdc-berlin.de.
Max Delbrück Center · DEBayer (Germany) · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEHarvard University Press · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe CRISPR/Cas9 system is increasingly used for gene inactivation in mouse zygotes, but homology-directed mutagenesis and use of inbred embryos are less established. In particular, Rosa26 knock-in alleles for the insertion of transgenes in a genomic 'safe harbor' site, have not been produced. Here we applied CRISPR/Cas9 for the knock-in of 8-11 kb inserts into Rosa26 of C57BL/6 zygotes.

resultsWe found that 10-20 % of live pups derived from microinjected zygotes were founder mutants, without apparent off-target effects, and up to 50 % knock-in embryos were recovered upon coinjection of Cas9 mRNA and protein. Using this approach, we established a new mouse line for the Cre/loxP-dependent expression of Cas9.

conclusionsAltogether, our protocols and resources support the fast and direct generation of new Rosa26 knock-in alleles and of Cas9-mediated in vivo gene editing in the widely used C57BL/6 inbred strain.

Indexed as

AnimalsCloning, MolecularCRISPR-Cas SystemsEmbryo, MammalianGene Knock-In TechniquesMiceMice, Inbred C57BLMicroinjectionsRNA, UntranslatedGt(ROSA)26Sor non-coding RNA, mouseRNA, Untranslated

Identifiers

PMID26772810
PMCPMC4715285
OpenAlexW2286099491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.